centrosomal protein 41Genealiases: JBTS15 · TSGA14
Q-omics provides the consensus-scored CEP41 profile across patient tissues and cancer cell-line models. CEP41 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CEP41 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, CEP41 RNA expression shows 20,051 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, BLCA, and ACC as cancer lineages where CEP41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP41 survival associations across molecular data types. CEP41 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP41 RNA expression–survival associations across cancer types. High CEP41 expression shows unfavorable associations in STAD, KICH, LIHC, HNSC and ACC, but favorable associations in READ. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for CEP41 RNA expression.
This table summarizes CEP41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CEP41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP41 shows higher tumor expression in BLCA, LUAD, LIHC, COAD, BRCA and CHOL. The BLCA box plot shows higher CEP41 RNA expression in tumor versus normal tissue (log2 FC = +0.780, t-test p < 0.001).
This table shows molecular features associated with CEP41 in patient tissues and cancer cell lines. In patient samples, CEP41 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP41 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
